No price history available.

Not enough data to calculate KvantraRank

Based on consensus from external analysts. Not Kvantra's opinion.

Operating from its Tokyo headquarters, Cytori Cell Research Institute, Inc., established in 2004 (originally FRACTALE Corporation), specializes in the comprehensive research, development, production, and distribution of medical devices related to cell therapy throughout Japan. The company offers various cell therapy kits and continuously advances cellular treatment technologies through ongoing research and development. Its active development pipeline includes ECCI-50, designed for the treatment of male stress urinary incontinence and hepatic cirrhosis, and Cyt-006, formulated to prevent postoperative adhesion after primary rectal cancer surgery. Additionally, Cytori conducts extensive clinical trials and investigations into cell-based therapies for a wide array of conditions and applications, such as the repair of anterior cruciate ligaments and bones, burn scar remediation, chronic wound healing, critical limb ischemia, treatment of anal and Crohn's disease fistulas, and erectile dysfunction. Beyond its primary biotechnological focus, the company also participates in the real estate sector, encompassing investment, ownership, development, leasing, and management of properties and hotels, as well as providing real estate brokerage services.

• Mereo BioPharma Group plc
• Kidswell Bio Corporation
• Andros Pharmaceuticals Co.,Ltd
• Covalon Technologies Ltd.
• Karyopharm Therapeutics Inc.
• Avecho Biotechnology Limited
• GenMont Biotech Incorporation
• Metagenomi, Inc. Common Stock